Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 2, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 6, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001759822-26-000002
Filed / recorded
Jan 6, 2026, 10:24 PM UTC
Added to OQRO
Oct 8, 2026, 12:20 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
DiaMedica Therapeutics Inc.
Issuer CIK
1401040
Ticker
DMAC
Reporting person
Randall Michael Giuffre
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jan 2, 2026
Transaction code
A
Shares / units
6,175
Price per share
$8.42
Acquired / disposed
Acquired (A)
Shares owned after
398,587
Ownership form
Direct
Amendment
No
Footnotes from the filing
Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $52,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.